Evvy

Executive Summary

Evvy is a New York-based diagnostics company pioneering precision vaginal healthcare through its proprietary Vaginal Microbiome Test and integrated clinical care platform. Founded in 2020, the company addresses a significant gap in women's health by providing at-home testing and prescription treatments for conditions like bacterial vaginosis (BV), yeast infections, and aerobic vaginitis. Trusted by over 75,000 users, Evvy combines state-of-the-art sequencing with telehealth-based clinical management, enabling personalized and accessible care. The company operates in a growing market driven by increasing awareness of the vaginal microbiome's role in overall health and rising demand for direct-to-consumer diagnostic solutions. Despite being a private entity with undisclosed funding and valuation, Evvy has demonstrated early traction and market validation. Its platform not only diagnoses but also offers treatment pathways, creating a vertically integrated model that improves patient outcomes and adherence. Looking ahead, Evvy is well-positioned to expand its test menu, secure partnerships with healthcare systems, and potentially pursue FDA clearance to strengthen clinical credibility. While competition exists from other microbiome and women's health startups, Evvy's focus on actionable treatment integration differentiates it. The company's growth will depend on scaling its user base, raising capital to fund operations and R&D, and navigating regulatory pathways. Overall, Evvy represents a promising player in the digital women's health space with considerable upside.

Upcoming Catalysts (preview)

• Q2 2026Series A or B Funding Round70% success
• Q4 2026FDA Clearance for Expanded Test Indications50% success
• Q3 2026Strategic Partnership with Major Healthcare Provider60% success